Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 45Leukemia 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Leukemia, Erythroblastic, Acute 14Leukemia, Myelomonocytic, Acute 13Leukemia, Monocytic, Acute 13Leukemia, Megakaryoblastic, Acute 13Congenital Abnormalities 11Myelodysplastic Syndromes 8Lymphoma 7Burkitt Lymphoma 7Anemia, Refractory, with Excess of Blasts 7Leukemia, Eosinophilic, Acute 5Myeloproliferative Disorders 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Biphenotypic, Acute 4Leukemia, Basophilic, Acute 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myelodysplastic-Myeloproliferative Diseases 3Neoplasm Metastasis 2Leukemia, Promyelocytic, Acute 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Down Syndrome 2Anemia, Refractory 2Sarcoma, Myeloid 1Sarcoma, Kaposi 1Sarcoma 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Neutropenia 1

Interventions

Dexamethasone 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1Vorinostat 1Rituximab 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Daunorubicin 1Cytarabine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Immunoproliferative Disorders × Daunorubicin × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡